NPM1 and acute myeloid leukemia: An APL‐like immunophenotype was previously described for AML with mutated NPM1, associated with significantly longer relapse‐free survival compared with patients lacking this phenotype (13) and a good response to all-trans retinoic acid (ATRA) therapy (14).